MacroGenics (MGNX)

Executive Summary

MacroGenics is a clinical-stage biopharmaceutical company advancing next-generation antibody-based therapeutics for oncology, leveraging its proprietary DART® and TRIDENT® platforms to develop bispecific, trispecific, and antibody-drug conjugates. The company's pipeline includes several Phase 2 candidates, notably lorigerlimab (a PD-1×CTLA-4 bispecific) and enoblituzumab (anti-B7-H3), which are being evaluated in prostate and ovarian cancers. A key near-term catalyst is the completion of a Phase 2 trial combining lorigerlimab with docetaxel in metastatic castration-resistant prostate cancer (NCT05848011), which concluded in March 2026, with data readout expected shortly. Additionally, enoblituzumab is being studied in multiple prostate cancer trials, with a Phase 2 study (NCT02923180) anticipated to report results around mid-2026. While MacroGenics has yet to secure an approved product, its innovative platforms and advancing clinical data position it for potential partnerships or regulatory milestones.

Upcoming Catalysts (preview)

• Q2 2026Lorigerlimab Phase 2 prostate cancer data readout40% success
• Q3 2026Enoblituzumab Phase 2 prostate cancer data from ongoing trial35% success
• H2 2026Lorigerlimab Phase 2 ovarian cancer interim data30% success